NZ592925A - Substituted pyrimidines for the treatment of diseases such as cancer - Google Patents

Substituted pyrimidines for the treatment of diseases such as cancer

Info

Publication number: NZ592925A
Authority: NZ; New Zealand
Prior art keywords: chloro; diseases; methyl; compounds; cancer
Prior art date: 2008-11-24

Application number

NZ592925A

Other languages

English (en)

Inventor

Heinz Stadtmueller

Ioannis Sapountzis

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-24

Filing date

2009-11-24

Publication date

2013-04-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115425&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ592925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-24 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2013-04-26 Publication of NZ592925A publication Critical patent/NZ592925A/xx

Links

201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
150000003230 pyrimidines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
UBVPWLAGRJRZEM-UHFFFAOYSA-N 2-chloro-4-[[5-chloro-4-[(2-methyl-3-oxo-1h-isoindol-4-yl)oxy]pyrimidin-2-yl]amino]-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound ClC=1C=C(NC=2N=C(OC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 UBVPWLAGRJRZEM-UHFFFAOYSA-N 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

NZ592925A 2008-11-24 2009-11-24 Substituted pyrimidines for the treatment of diseases such as cancer NZ592925A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08169807		2008-11-24
EP09169654		2009-09-07
PCT/EP2009/065768 WO2010058032A2 (en)	2008-11-24	2009-11-24	New compounds

Publications (1)

Publication Number	Publication Date
NZ592925A true NZ592925A (en)	2013-04-26

Family

ID=42115425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ592925A NZ592925A (en)	2008-11-24	2009-11-24	Substituted pyrimidines for the treatment of diseases such as cancer

Country Status (27)

Country	Link
US (4)	US8846689B2 (zh)
EP (1)	EP2367800B9 (zh)
JP (1)	JP5622740B2 (zh)
KR (1)	KR101710058B1 (zh)
CN (2)	CN104478865B (zh)
AP (1)	AP2960A (zh)
AR (1)	AR074210A1 (zh)
AU (1)	AU2009317170B2 (zh)
BR (1)	BRPI0922801B1 (zh)
CA (1)	CA2744351C (zh)
CL (1)	CL2011001215A1 (zh)
CO (1)	CO6511283A2 (zh)
EA (1)	EA021997B1 (zh)
EC (1)	ECSP11011079A (zh)
ES (1)	ES2664499T3 (zh)
GE (1)	GEP20146072B (zh)
HK (1)	HK1160841A1 (zh)
IL (1)	IL212814B (zh)
MA (1)	MA32811B1 (zh)
MX (1)	MX337116B (zh)
MY (1)	MY176944A (zh)
NZ (1)	NZ592925A (zh)
PE (1)	PE20120034A1 (zh)
TN (1)	TN2011000259A1 (zh)
TW (1)	TWI491605B (zh)
UY (1)	UY32259A (zh)
WO (1)	WO2010058032A2 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI491605B (zh)	2008-11-24	2015-07-11	Boehringer Ingelheim Int	新穎化合物
AR074209A1 (es)	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina utiles para el tratamiento del cancer
US8933227B2 (en)	2009-08-14	2015-01-13	Boehringer Ingelheim International Gmbh	Selective synthesis of functionalized pyrimidines
EP2464633A1 (en)	2009-08-14	2012-06-20	Boehringer Ingelheim International GmbH	Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CN103534240B (zh) *	2011-02-17	2015-12-09	癌症疗法Crc私人有限公司	选择性fak抑制剂
EP2675793B1 (en)	2011-02-17	2018-08-08	Cancer Therapeutics Crc Pty Limited	Fak inhibitors
JPWO2013146963A1 (ja) *	2012-03-28	2015-12-14	武田薬品工業株式会社	複素環化合物
SI3043784T1 (sl)	2013-09-09	2019-08-30	Peloton Therapeutics, Inc.	Aril etri in njihova uporaba
WO2016144826A1 (en)	2015-03-11	2016-09-15	Peloton Therapeutics, Inc.	Substituted pyridines and uses thereof
WO2016144825A1 (en)	2015-03-11	2016-09-15	Peloton Therapeutics, Inc.	Aromatic compounds and uses thereof
US10512626B2 (en)	2015-03-11	2019-12-24	Peloton Therapeautics, Inc.	Compositions for use in treating glioblastoma
EP3267792A4 (en)	2015-03-11	2018-09-26	Peloton Therapeutics, Inc.	Compositions for use in treating pulmonary arterial hypertension
US10335388B2 (en)	2015-04-17	2019-07-02	Peloton Therapeutics, Inc.	Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20170066778A1 (en) *	2015-09-04	2017-03-09	Aunova Medchem LLC	Solubility for target compounds
US20230145356A1 (en)	2019-11-18	2023-05-11	Inxmed (Nanjing) Co., Ltd.	Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
WO2021104454A1 (zh) *	2019-11-28	2021-06-03	应世生物科技(南京)有限公司	Bi853520在癌症治疗中的用途
US20230079055A1 (en) *	2020-02-05	2023-03-16	Inxmed (Nanjing) Co., Ltd.	Combination of bi853520 with chemotherapeutic drugs
KR20230048089A (ko) *	2020-08-03	2023-04-10	인엑스메드 (난징) 컴퍼니 리미티드	화합물의 고체 형태
WO2023020291A1 (zh) *	2021-08-16	2023-02-23	应世生物科技(南京)有限公司	In10018与pld的联用
WO2023116527A1 (zh) *	2021-12-21	2023-06-29	微境生物医药科技(上海)有限公司	作为fak抑制剂的化合物及其用途
WO2023160614A1 (zh) *	2022-02-28	2023-08-31	微境生物医药科技(上海)有限公司	作为fak抑制剂的化合物及其用途
WO2023246869A1 (zh) *	2022-06-24	2023-12-28	应世生物科技(南京)有限公司	***的药物组合及用途
CN117462553A (zh) *	2022-07-20	2024-01-30	益方生物科技(上海)股份有限公司	药物组合产品以及组合疗法
WO2024041527A1 (zh) *	2022-08-24	2024-02-29	应世生物科技(南京)有限公司	Fak抑制剂及微管抑制剂的药物组合及用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
WO2000012485A1 (en)	1998-08-29	2000-03-09	Astrazeneca Ab	Pyrimidine compounds
US6906067B2 (en) *	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
GB0004886D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
EP2090571B1 (de)	2001-10-17	2012-05-16	Boehringer Ingelheim Pharma GmbH & Co. KG	Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
US7504410B2 (en)	2002-11-28	2009-03-17	Schering Aktiengesellschaft	Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
ATE433447T1 (de)	2003-02-20	2009-06-15	Smithkline Beecham Corp	Pyrimiidinverbindungen
CL2004000303A1 (es) *	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7504396B2 (en) *	2003-06-24	2009-03-17	Amgen Inc.	Substituted heterocyclic compounds and methods of use
SG145749A1 (en)	2003-08-15	2008-09-29	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1598343A1 (de)	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) *	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
GB0419160D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
CN101031550B (zh)	2004-09-30	2015-05-27	泰博特克药品有限公司	抑制hiv的5-碳环-或杂环取代的嘧啶类
CN101103028A (zh)	2005-01-14	2008-01-09	神经能质公司	经杂芳基取代的喹啉-4-基氨类似物
US20070032514A1 (en)	2005-07-01	2007-02-08	Zahn Stephan K	2,4-diamino-pyrimidines as aurora inhibitors
US20090149467A1 (en)	2005-09-15	2009-06-11	Merck & Co., Inc.	Tyrosine Kinase Inhibitors
JP2009520038A (ja)	2005-12-19	2009-05-21	ジェネンテック・インコーポレーテッド	ピリミジンキナーゼインヒビター
FR2896503B1 (fr) *	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7569561B2 (en)	2006-02-22	2009-08-04	Boehringer Ingelheim International Gmbh	2,4-diaminopyrimidines useful for treating cell proliferation diseases
EA016264B1 (ru)	2006-03-31	2012-03-30	Янссен Фармацевтика Н.В.	Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н
GB0619343D0 (en)	2006-09-30	2006-11-08	Vernalis R&D Ltd	New chemical compounds
WO2008040951A1 (en)	2006-10-03	2008-04-10	Astrazeneca Ab	Compounds
CN101553483B (zh)	2006-12-13	2013-04-17	弗·哈夫曼-拉罗切有限公司	作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
CA2670645A1 (en)	2006-12-19	2008-07-03	Genentech, Inc.	Pyrimidine kinase inhibitors
WO2008092199A1 (en)	2007-01-31	2008-08-07	Cytopia Research Pty Ltd	Thiopyrimidine-based compounds and uses thereof
MX2009011199A (es) *	2007-04-16	2010-03-17	Hutchison Medipharma Entpr Ltd	Derivados de pirimidina.
JP2011515372A (ja)	2008-03-20	2011-05-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	置換ピリミジン類の位置選択的製造法
KR20110025224A (ko)	2008-06-27	2011-03-09	아빌라 테라퓨틱스, 인크.	헤테로아릴 화합물 및 이의 용도
TWI491605B (zh)	2008-11-24	2015-07-11	Boehringer Ingelheim Int	新穎化合物
AR074209A1 (es)	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina utiles para el tratamiento del cancer
WO2010129053A2 (en)	2009-05-05	2010-11-11	Dana Farber Cancer Institute	Egfr inhibitors and methods of treating disorders

2009
- 2009-11-23 TW TW098139766A patent/TWI491605B/zh active
- 2009-11-23 AR ARP090104511A patent/AR074210A1/es not_active Application Discontinuation
- 2009-11-24 EA EA201100794A patent/EA021997B1/ru not_active IP Right Cessation
- 2009-11-24 MX MX2011005420A patent/MX337116B/es active IP Right Grant
- 2009-11-24 PE PE2011001080A patent/PE20120034A1/es active IP Right Grant
- 2009-11-24 EP EP09756513.9A patent/EP2367800B9/en active Active
- 2009-11-24 UY UY0001032259A patent/UY32259A/es not_active Application Discontinuation
- 2009-11-24 ES ES09756513.9T patent/ES2664499T3/es active Active
- 2009-11-24 AP AP2011005706A patent/AP2960A/xx active
- 2009-11-24 BR BRPI0922801-2A patent/BRPI0922801B1/pt active IP Right Grant
- 2009-11-24 US US13/130,669 patent/US8846689B2/en active Active
- 2009-11-24 CA CA2744351A patent/CA2744351C/en active Active
- 2009-11-24 CN CN201410635154.8A patent/CN104478865B/zh active Active
- 2009-11-24 JP JP2011536901A patent/JP5622740B2/ja active Active
- 2009-11-24 CN CN200980155031.1A patent/CN102292322B/zh active Active
- 2009-11-24 KR KR1020117014264A patent/KR101710058B1/ko active IP Right Grant
- 2009-11-24 MY MYPI2011002290A patent/MY176944A/en unknown
- 2009-11-24 NZ NZ592925A patent/NZ592925A/xx unknown
- 2009-11-24 WO PCT/EP2009/065768 patent/WO2010058032A2/en active Application Filing
- 2009-11-24 GE GEAP200912270A patent/GEP20146072B/en unknown
- 2009-11-24 AU AU2009317170A patent/AU2009317170B2/en active Active
2011
- 2011-05-11 IL IL212814A patent/IL212814B/en active IP Right Grant
- 2011-05-20 MA MA33866A patent/MA32811B1/fr unknown
- 2011-05-20 TN TN2011000259A patent/TN2011000259A1/fr unknown
- 2011-05-24 CL CL2011001215A patent/CL2011001215A1/es unknown
- 2011-05-24 CO CO11063881A patent/CO6511283A2/es not_active Application Discontinuation
- 2011-05-24 EC EC2011011079A patent/ECSP11011079A/es unknown
2012
- 2012-02-07 HK HK12101136.9A patent/HK1160841A1/zh unknown
2014
- 2014-08-29 US US14/472,627 patent/US20140371205A1/en not_active Abandoned
2015
- 2015-09-04 US US14/845,529 patent/US20150376141A1/en not_active Abandoned
2016
- 2016-08-24 US US15/245,854 patent/US9676762B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MX337116B (es)	2016-02-12
EP2367800A2 (en)	2011-09-28
MY176944A (en)	2020-08-27
US20110288071A1 (en)	2011-11-24
CL2011001215A1 (es)	2011-09-30
JP2012509864A (ja)	2012-04-26
KR101710058B1 (ko)	2017-02-24
TN2011000259A1 (en)	2012-12-17
EA201100794A1 (ru)	2012-01-30
UY32259A (es)	2010-06-30
US8846689B2 (en)	2014-09-30
IL212814A0 (en)	2011-07-31
MA32811B1 (fr)	2011-11-01
EA021997B1 (ru)	2015-10-30
TW201026682A (en)	2010-07-16
CN104478865B (zh)	2017-09-22
BRPI0922801A2 (pt)	2020-08-04
CN102292322B (zh)	2015-11-25
JP5622740B2 (ja)	2014-11-12
GEP20146072B (en)	2014-04-10
CN104478865A (zh)	2015-04-01
WO2010058032A2 (en)	2010-05-27
ECSP11011079A (es)	2011-06-30
AP2960A (en)	2014-08-31
BRPI0922801B1 (pt)	2021-12-21
US9676762B2 (en)	2017-06-13
CO6511283A2 (es)	2012-08-31
KR20110084551A (ko)	2011-07-25
ES2664499T9 (es)	2022-01-03
AR074210A1 (es)	2010-12-29
MX2011005420A (es)	2011-06-16
US20140371205A1 (en)	2014-12-18
US20160362404A1 (en)	2016-12-15
AU2009317170A1 (en)	2010-05-27
AP2011005706A0 (en)	2011-06-30
WO2010058032A3 (en)	2010-07-15
CA2744351A1 (en)	2010-05-27
IL212814B (en)	2018-05-31
AU2009317170B2 (en)	2015-05-28
TWI491605B (zh)	2015-07-11
CN102292322A (zh)	2011-12-21
ES2664499T3 (es)	2018-04-19
HK1160841A1 (zh)	2012-08-17
US20150376141A1 (en)	2015-12-31
CA2744351C (en)	2017-07-04
EP2367800B1 (en)	2018-02-28
PE20120034A1 (es)	2012-02-19
EP2367800B9 (en)	2021-10-20

Legal Events

Date	Code	Title	Description
2013-08-30	PSEA	Patent sealed
2013-09-27	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 NOV 2016 BY SPRUSON + FERGUSON Effective date: 20130906
2016-10-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2017 BY DENNEMEYER + CO. Effective date: 20161021
2017-10-27	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2018 BY DENNEMEYER + CO Effective date: 20171025
2018-10-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2019 BY DENNEMEYER + CO Effective date: 20181020
2019-10-25	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2020 BY DENNEMEYER + CO Effective date: 20191022
2020-11-27	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2021 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20201117
2021-11-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2022 BY DENNEEMYER + CO Effective date: 20211115
2022-11-25	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2023 BY DENNEMEYER + CO. Effective date: 20221114
2023-05-26	ASS	Change of ownership	Owner name: INXMED (HONG KONG) LIMITED, HK Effective date: 20230523
2023-11-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2024 BY DENNEMEYER + CO. SARL Effective date: 20231114

Publication	Publication Date	Title
NZ592925A (en)	2013-04-26	Substituted pyrimidines for the treatment of diseases such as cancer
MX2009009590A (es)	2009-11-10	Aminopirimidinas utiles como inhibidores de proteinas cinasas.
UA99833C2 (en)	2012-10-10	Pyrimidinyl pyridazinone derivates
MX2011012353A (es)	2011-12-14	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
ATE526328T1 (de)	2011-10-15	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2009010037A (es)	2009-11-05	Aminopirimidinas utiles como inhibidores de cinasas.
MX2009013077A (es)	2010-01-15	Derivados dde benzoxazolona.
ATE474835T1 (de)	2010-08-15	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
UA99311C2 (en)	2012-08-10	Inhibitors of c-fms kinase
ATE508126T1 (de)	2011-05-15	Als kinaseinhibitoren geeignete aminopyrimidine
TW200716118A (en)	2007-05-01	Aminopyrimidines as kinase modulators
TW200736250A (en)	2007-10-01	Aminopyrimidines useful as kinase inhibitors
TW200718693A (en)	2007-05-16	Aminopyrimidines as kinase modulators
MX2009011811A (es)	2010-01-14	Aminopirimidinas utiles como inhibidores de cinasa.
MX2009004807A (es)	2009-06-15	Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
MY155719A (en)	2015-11-30	2-benzylpyridazinone derivatives as met kinase inhibitors
MX2010009207A (es)	2011-03-03	Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
IL201365A0 (en)	2010-05-31	Pyrimidine derivatives as inhibitors of phosphatidylinositol - 3 kinase
MX2009012708A (es)	2009-12-08	Derivados de piridazinona.
WO2008148867A3 (en)	2009-04-09	Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of janus kinases
WO2008017361A3 (de)	2008-06-12	2-(heterocyclylbenzyl)-pyridazinonderivate
NZ598614A (en)	2013-08-30	Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
TN2010000070A1 (en)	2011-09-26	Fused bicyclic pyrimidines
MX2009011059A (es)	2009-11-26	Aminopirimidinas utiles como inhibidores de cinasas.
MX2012012031A (es)	2012-12-17	Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.